Results 201 to 210 of about 24,338 (259)

Exploring the Value of Quantitative Muscle Ultrasound in Neuromuscular Junction Disorders: A Pilot Study

open access: yesMuscle &Nerve, Volume 74, Issue 4, Page 1281-1287, October 2026.
ABSTRACT Introduction/Aims Quantitative muscle ultrasound (QMUS) is a validated technique for assessing muscle pathology, yet its role in disorders primarily affecting the neuromuscular junction (NMJ) remains unclear. This pilot study aimed to explore whether QMUS is associated with structural muscle changes in patients with acquired or genetic NMJ ...
Artor Pogosean   +3 more
wiley   +1 more source

Post‐Transplant Bendamustine as a Platform for Immune Modulation After Allogeneic Hematopoietic Cell Transplantation

open access: yesEuropean Journal of Haematology, Volume 117, Issue 4, Page 739-749, October 2026.
ABSTRACT Post‐transplant cyclophosphamide (PT‐CY) remains the standard of care for graft‐versus‐host disease (GvHD) prophylaxis in haploidentical hematopoietic cell transplantation (HCT), yet relapse, delayed immune reconstitution, infections, and organ toxicity represent persistent and clinically meaningful limitations.
Megan J. Cracchiolo   +2 more
wiley   +1 more source

Manufacturing and clinical applications of non‐CAR‐T immune effector cells

open access: yes
Transfusion, EarlyView.
Thane Kubik   +2 more
wiley   +1 more source

Third Allogeneic Stem Cell Transplantation in Children: A Multicenter Analysis From the Spanish GETH‐TC Pediatric Group

open access: yesEuropean Journal of Haematology, Volume 117, Issue 4, Page 943-952, October 2026.
ABSTRACT Third allogeneic hematopoietic stem cell transplantation (HSCT3) is rarely performed in pediatric patients and is associated with high toxicity and mortality. Data on outcomes in this setting remain scarce. We conducted a retrospective multicenter study within the Spanish GETH‐TC Pediatric group including 29 children and adolescents who ...
Luisa Sisinni   +17 more
wiley   +1 more source

[Seropositive syphilis in pregnancy].

open access: yesTidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2004
openaire   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Disclosure of HIV seropositivity

Journal of Clinical Psychology, 1999
Deciding whether or not to disclose one's HIV-positive status to another person is an important decision: the way each person experiences and copes with the illness is reflected in this choice. We conducted a study of 174 patients (29.3% of women) to examine how the decision to disclose or conceal was made, as well as its subjective and social ...
A, Lévy   +6 more
openaire   +2 more sources

MANAGEMENT OF RETINOBLASTOMA WITH HIV SEROPOSITIVITY

RETINAL Cases & Brief Reports, 2020
Purpose: To report a case of retinoblastoma with concomitant association with HIV seropositivity and its management. Methods: A retrospective case report of a 3-year-old male child presenting with right eye Group B and left eye Group E retinoblastoma with simultaneous positivity for
Abhinav, Dhami   +2 more
openaire   +2 more sources

Leptospiral infection and seropositivity in rodents

Preventive Veterinary Medicine, 2004
Leblebicioglu, Hakan/0000-0002-6033 ...
Leblebicioglu, H, Sunbul, M
openaire   +2 more sources

Seropositivity for HIV at Alternate Sites

JAMA: The Journal of the American Medical Association, 1988
To the Editor.— Shortly after the Food and Drug Administration licensed thetubeenzyme-linked immunosorbent assay for human immunodeficiency virus (HIV) testing, the Centers for Disease Control made funds available for the development and implementation of "alternate testing sites." The goal of the program was to protect the nation's blood supply by ...
J C, Grabau, D L, Morse
openaire   +2 more sources

HIV-seropositive thrombocytopenia

AIDS, 1991
The action of zidovudine when administered to individuals with severe HIV thrombocytopenia was investigated. Four individuals with platelets less than 50 x 10(9)/l and CD4 cells greater than 200 x 10(6)/l were treated with 600 mg zidovudine per day for 6 weeks, no drug for 6 weeks, 1200 mg zidovudine per day for 6 weeks, then no drug for 6 weeks ...
A, Boyar, G, Beall
openaire   +2 more sources

Home - About - Disclaimer - Privacy